Anemia Management News

Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine, reported that roxadustat was not linked to increased risk for neoplasm in patients with nondialysis- and dialysis-dependent chronic kidney disease.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine, discussed the insufficiency of current anemia treatment for non-dialysis-dependent patients with chronic kidney disease.

In a video, Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine reports the efficacy of vadadustat in treating anemia in patients with dialysis-dependent chronic kidney disease is noninferior to darbepoetin alfa.

Vadadustat is noninferior to darbepoetin alfa in preserving hemoglobin levels in patients with nondialysis-dependent chronic kidney disease and anemia who were or were not treated with erythropoiesis-stimulating agents prior, a study shows.

Patients who underwent dialysis and were prescribed roxadustat had a 27% reduction in risk for hospitalization for congestive heart failure compared with patients who took epoetin alfa, according to a study.

Patients with anemia of CKD who receive roxadustat showed a lower level of adverse cardiovascular events when hemoglobin levels were maintained at 10 g/dL or higher, according to data presented at ASN Kidney Week.

Patients with anemia and chronic kidney disease who receive roxadustat do not show an increased rate of neoplasm-related treatment-emergent adverse events and treatment-emergent serious adverse events, according to presented data.

Vadadustat demonstrated the efficacy and cardiovascular safety for the treatment of anemia in adult patients with dialysis-dependent chronic kidney disease, according to recently presented data.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discusses challenges of anemia management in CKD.

In this video, Jay B. Wish, MD, professor of clinical medicine at Indiana University School of Medicine and chief medical officer for dialysis at Indiana University Health in Indianapolis, discussed treatment approaches for patients at risk for cardiovascular complications.